Cardiology (all articles)
Podcast: No tension about inpatient hypertension.
14 Dec, 2021 | 08:39h | UTC#310 No Tension About Inpatient Hypertension with Dr. Noble Maleque – The Curbsiders
Pooled analysis of randomized trials on the effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction (EF) showed the effects were clinically meaningful and similar in patients with EF below 65% but were attenuated in patients with EF above 65%.
13 Dec, 2021 | 08:53h | UTC
Commentary on Twitter
Effect of empagliflozin on heart failure hospitalizations: news from the pooled analysis on both the EMPEROR-Reduced and EMPEROR-Preserved trials! #empaglifozin #heart #failure #hospitalization#ehj #cardiotwitter@escardio @ESC_Journals https://t.co/W6FuYbwVzx pic.twitter.com/5qLXDVaC89
— EHJ Editor-in-Chief (@ehj_ed) December 11, 2021
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization.
10 Dec, 2021 | 10:11h | UTCGuideline Hub: 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization
Executive Summary: 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization
News release: Coronary Revascularization the Focus of New ACC/AHA Clinical Guideline
ACC/AHA Slide Set: 2021 ACC/AHA/SCAI Guidelines for Coronary Artery Revascularization
Top Things to Know: 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization
Key Perspectives: ACC/AHA/SCAI Coronary Revascularization Guideline
Commentary on Twitter
🆕 ACC/@American_Heart/@SCAI #ClinicalGuidelines for Coronary Artery Revascularization released today. This guideline provides a patient-centric approach to guide clinicians in the treatment of patients undergoing #Revasc. Access the full guideline here: https://t.co/rr6TI5kFzI pic.twitter.com/f3xdTFAaUi
— American College of Cardiology (@ACCinTouch) December 9, 2021
M-A: Performance of the European Society of Cardiology 0/1-hour, 0/2-hour, and 0/3-hour algorithms for rapid triage of acute myocardial infarction.
10 Dec, 2021 | 10:09h | UTCPerformance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction: An International Collaborative Meta-analysis – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentaries:
Rapid ESC hs-cTn Algorithms Best 3-Hour Protocol for MI Rule-out: Meta-analysis – TCTMD
Performance of ESC 0/1-, 0/2-, 0/3-Hour Algorithms for AMI Compared – HealthDay
Commentary on Twitter
New meta-analysis published this week confirms new algorithms proposed by @escardio for ruling out #myocardialinfarction are more accurate than the previously preferred diagnostic tool: https://t.co/lAnozWXuOF pic.twitter.com/v2JGjyPRRW
— Annals of Int Med (@AnnalsofIM) November 25, 2021
M-A: Intravenous diltiazem vs. metoprolol for atrial fibrillation with rapid ventricular rate.
10 Dec, 2021 | 10:05h | UTCIntravenous diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate: A meta-analysis – The American Journal of Emergency Medicine (link to abstract – $ for full-text)
Life expectancy after surgical aortic valve replacement.
10 Dec, 2021 | 10:06h | UTC
Recommended standards for the performance of transesophageal echocardiographic screening for structural heart intervention.
9 Dec, 2021 | 10:11h | UTC
Commentary on Twitter
New TEE in Structural Heart Intervention Guideline Now Available Online: https://t.co/BtqTHmSNHY
Lead author @hahn_rt will present 2 webinars on this guideline Dec. 15 & 17. Save the date. Registration will open soon! pic.twitter.com/GL9ndSini6— American Society of Echocardiography (@ASE360) November 18, 2021
Prevention and management of hyperkalemia in patients treated with renin–angiotensin–aldosterone system inhibitors.
8 Dec, 2021 | 09:58h | UTC
ESC Position Paper: Optimal follow-up after acute pulmonary embolism.
8 Dec, 2021 | 10:02h | UTC
Commentary on Twitter
Do you routinely discuss how/when to resume sporting activities and traveling with your PE patients? Or future cardiovascular risk? Check this recent ESC/ERS position paper on optimal follow-up of acute PE for these and other key aspects of counselling: https://t.co/KEQ7FnFwXX
— Erik Klok (@Erik_Klok_MD) December 7, 2021
What Is of Recent Interest in Cardiac Imaging?: Insights From the JACC Family of Journals.
8 Dec, 2021 | 09:54h | UTC
Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.
7 Dec, 2021 | 10:19h | UTCNews Release: Young people recover quickly from rare myocarditis side effect of COVID-19 vaccine – American Heart Association
Cohort Study: Among asymptomatic individuals that have undergone treadmill testing, high-grade premature ventricular contractions occurring during recovery were associated with increased risk of cardiovascular mortality.
5 Dec, 2021 | 23:42h | UTCExercise-Induced Ventricular Ectopy and Cardiovascular Mortality in Asymptomatic Individuals – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Commentary: Exercise-Induced Ventricular Ectopy and Cardiovascular Mortality – American College of Cardiology
Review | Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification.
5 Dec, 2021 | 23:40h | UTCVideo: Radiation Therapy and Cardiovascular Disease | JACC: CardioOncology Author Discussion
Related:
Radiation‐induced cardiovascular disease: review of an underrecognized pathology.
Short review: How to diagnose and manage radiation therapy cardiotoxicity
Cohort Study: Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients with Lung Cancer
Association of resting heart rate with cognitive decline and dementia in older adults: A population-based cohort study.
5 Dec, 2021 | 23:17h | UTCNews Release: Elevated heart rate linked to increased risk of dementia – Karolinska Intitutet
Practical recommendations on quantifying and interpreting treatment effects in the presence of terminal competing risks.
3 Dec, 2021 | 10:07h | UTCPractical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks: A Review – JAMA Cardiology (free for a limited period)
Commentary on Twitter
Our paper on how to analyze and interpret terminal competing risks in cardiovascular clinical trials just out in JAMA Cardiology. Always a pleasure to collaborate with LJ Wei, Marc Pfeffer and Scott Solomon and their great teams. https://t.co/9hk6wru7yU pic.twitter.com/64sgoOjldQ
— Otavio Berwanger (@OtavioBerwanger) December 1, 2021
AHA Scientific Statement: Supporting physical activity in patients and populations during life events and transitions.
2 Dec, 2021 | 09:53h | UTCNews Release: Major life events influence level of physical activity, may negatively impact heart health – American Heart Association
The ‘ten commandments’ for the 2021 ESC Guidelines on CVD prevention.
2 Dec, 2021 | 09:45h | UTCThe ‘ten commandments’ for the 2021 ESC Guidelines on CVD prevention – European Heart Journal
Original Article: #ESCCongress – 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
Electrocardiogram monitoring in the prone position in Covid-19 acute respiratory distress syndrome.
30 Nov, 2021 | 08:38h | UTC
Commentary on Twitter
Prone position alters #ECG in patients with #COVID19 ARDS. Read this short report from #EJCN: https://t.co/ySbIsS0Abf@escardio @ACNAPPresident @EditorEJCN #ACNAP @LeonieKlompstra #cardiotwitter pic.twitter.com/1GxEZB2Cpf
— European Society of Cardiology Journals (@ESC_Journals) November 27, 2021
Cohort study found the risk of myocardial infarction may be best predicted by the number of apolipoprotein B containing lipoproteins.
24 Nov, 2021 | 08:41h | UTCAssociation of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content – JAMA Cardiology (link to abstract – $ for full-text)
Commentaries:
ApoB Gains Ground as Best Lipid Predictor of MI Risk – TCTMD
Study finds risk of MI best captured by number of apolipoprotein B lipoproteins – MedicalResearch
Commentary on Twitter
Study from @marstonMD @TIMIStudyGroup et al found lipid-associated risk for myocardial infarction is best captured by the number of apoB-containing lipoproteins, independent from lipid content (cholesterol or TG) or type of lipoprotein (LDL or TG-rich) https://t.co/UBby6mtj6e
— JAMA Cardiology (@JAMACardio) November 13, 2021
Systematic Review: Renal denervation may have a modest effect in improving 24h ambulatory blood pressure monitoring (reduction in SBP by 5.29 mmHg and DBP by 3.75 mmHg) but does not improve major cardiovascular outcomes and renal function.
24 Nov, 2021 | 08:33h | UTCOriginal Review: Renal denervation for resistant hypertension – Cochrane Library
Commentary on Twitter
https://twitter.com/CochraneHTN/status/1462979551558995971
Chest Pain: Who needs additional testing beyond ECG and Troponin?
24 Nov, 2021 | 08:28h | UTCChest Pain: Who Needs Additional Testing Beyond ECG and Troponin? – JACC: Case Reports
Review: Prevention and treatment of atrial fibrillation via risk factor modification.
24 Nov, 2021 | 08:25h | UTC
In a survey of about 27,600 U.S. individuals, 18.5% of adults with hypertension used medications that may raise blood pressure; the most commonly reported classes were antidepressants, nonsteroidal anti-inflammatory drugs, steroids, and estrogens.
23 Nov, 2021 | 08:33h | UTCPrevalence of Medications That May Raise Blood Pressure Among Adults With Hypertension in the United States – JAMA Internal Medicine (free for a limited period)
Commentary from the author on Twitter (thread – click for more)
🚨New work from our team in @JAMAInternalMed 🚨
18% of adults with #hypertension report using medications (💊) that may raise blood pressure.
Use of these 💊 associated with:
⬇️ odds of achieving BP control
⬆️ # of antihypertensives usedhttps://t.co/DlV5rlHLu3Thread
/1 pic.twitter.com/q7b7FQ4jHH— Tim Anderson (@TimAndersonMD) November 22, 2021
M-A: In patients with Non-ST Elevation Acute Coronary Syndromes, pretreatment with oral P2Y12 inhibitors prior to angiography was associated with increased risk of bleeding and no difference in cardiovascular outcomes.
21 Nov, 2021 | 22:58h | UTCInvited Commentary: Pretreatment in the Setting of Non–ST-Elevated Acute Coronary Syndrome—When It Is Time to Change – JAMA Network Open
RCT: In patients with heart failure and preserved ejection fraction, Sacubitril/Valsartan reduced NT-proBNP, but did not improve exercise capacity and was associated with increased risk of hypotension (14.1% vs 5.5%).
19 Nov, 2021 | 10:27h | UTCEffect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Quality of Life and Exercise Ability in Heart Failure With Preserved Ejection Fraction: No Time for Therapeutic Complacency – JAMA (free for a limited period)
Commentary on Twitter
Study found treatment w sacubitril/valsartan vs standard treatment w enalapril, valsartan, or placebo resulted in a statistically significant reduction in plasma NT-proBNP levels at 12 wk but no significant change in the 6-minute walking distance at 24 wk https://t.co/rwlOXWwcz2 pic.twitter.com/fRUPgQpU9J
— JAMA (@JAMA_current) November 16, 2021


